BIIB : Summary for Biogen Inc. - Yahoo Finance

U.S. Markets closed

Biogen Inc. (BIIB)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
287.75-1.79 (-0.62%)
At close: 4:00 PM EST
People also watch:
CELGGILDREGNAMGNALXN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close289.54
Open305.24
Bid285.25 x 100
Ask291.19 x 100
Day's Range281.79 - 306.98
52 Week Range223.02 - 333.65
Volume6,090,619
Avg. Volume1,674,128
Market Cap62.61B
Beta0.33
PE Ratio (TTM)16.27
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is Biogen's Aducanumab a Game-Changing Alzheimer's Drug?
    Motley Foolyesterday

    Is Biogen's Aducanumab a Game-Changing Alzheimer's Drug?

    The biotech has updated research suggesting its new clinical-stage drug could slow down Alzheimer's disease progression.

  • Biogen Underplays Promising Alzheimer's Data On Seizure Worries
    Investor's Business Daily2 days ago

    Biogen Underplays Promising Alzheimer's Data On Seizure Worries

    Biogen stock underplayed promising Alzheimer's Disease drug results on investor concern over a patient seizure.

  • Barrons.com2 days ago

    Biotech ETFs: A Short-Lived Boon From Biogen

    Earlier today, Barron’s weighed in, calling Biogen “a biotech bargain.” But Biogen’s share price ended the day in the red as some investors engaged in profit taking and others reacted (some say overreacted) to questions about safety. Biogen’s initial share price surge helped to lift the bio biotech exchange-traded funds at a clip that dramatically outpaced the broader market. ProShares Ultra Nasdaq Biotech (BIB) rose as much as 4.9% Friday morning, while the iShares Nasdaq Biotechnology ETF (IBB) and the SPDR S&P Biotech (XBI) each climbed more than 2.4% All three ETFs gave up all, or most of those gains by the closing bell.